Get the Stockscreener App
2.15
0.00%
0.00
After Hours:
2.16
0.01
+0.47%
Nls Pharmaceutics Ltd stock is traded at $2.15, with a volume of 138.09K.
It is up +0.00% in the last 24 hours and up +0.94% over the past month.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$2.15
Open:
$2.12
24h Volume:
138.09K
Relative Volume:
0.65
Market Cap:
$7.73M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-4.30
EPS:
-0.5
Net Cash Flow:
$-13.51M
1W Performance:
+9.69%
1M Performance:
+0.94%
6M Performance:
+33.54%
1Y Performance:
-59.28%
1-Day Range:
$2.1004
$2.2407
1-Week Range:
$1.93
$2.2407
52-Week Range:
$1.30
$6.972
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
2.15 | 10.16M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
Published on: 2025-09-12 19:12:43 - Newser
Using economic indicators to assess NLS Pharmaceutics AG potentialPortfolio Gains Report & Weekly Stock Performance Updates - Newser
Applying big data sentiment scoring on NLS Pharmaceutics AG2025 Market Overview & Consistent Income Trade Ideas - Newser
Published on: 2025-09-12 12:36:54 - Newser
Using flow based indicators on NLS Pharmaceutics AG Equity WarrantWeekly Profit Report & Daily Growth Stock Investment Tips - Newser
Leading vs lagging indicators on NLS Pharmaceutics AG performanceDividend Hike & Daily Entry Point Trade Alerts - Newser
Published on: 2025-09-12 04:04:33 - Newser
Can a trend reversal in NLS Pharmaceutics AG Equity Warrant lead to recoveryJuly 2025 Gainers & Technical Entry and Exit Tips - Newser
Does NLS Pharmaceutics AG qualify in momentum factor screeningIndex Update & Technical Pattern Based Buy Signals - Newser
Tick level data insight on NLS Pharmaceutics AG Equity Warrant volatilityPortfolio Profit Report & Technical Entry and Exit Alerts - Newser
NLS Pharmaceutics AG stock chart pattern explainedWeekly Trade Analysis & Consistent Growth Stock Picks - Newser
Is now a turning point for NLS Pharmaceutics AGJuly 2025 Big Picture & Growth-Oriented Investment Plans - Newser
Understanding NLS Pharmaceutics AG’s price movementLong Setup & Weekly Watchlist of Top Performers - Newser
NLS Pharmaceutics and Kadimastem Secure SEC Approval for Merger - MSN
Statistical indicators supporting NLS Pharmaceutics AG’s strengthPortfolio Gains Report & Daily Technical Stock Forecast Reports - Newser
Real time pattern detection on NLS Pharmaceutics AG stockJuly 2025 Summary & High Conviction Buy Zone Alerts - Newser
Kadimastem and NLS Pharmaceutics Merger Update - citybiz
SEC clears registration for NLS Pharmaceutics and Kadimastem merger By Investing.com - Investing.com Canada
SEC clears registration for NLS Pharmaceutics and Kadimastem merger - Investing.com
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger - Yahoo Finance
Top chart patterns to watch in NLS Pharmaceutics AGPortfolio Value Summary & Fast Exit and Entry Strategy Plans - Newser
How institutional ownership impacts NLS Pharmaceutics AG stockDip Buying & Reliable Entry Point Alerts - Newser
Published on: 2025-09-10 00:53:11 - Newser
Real time alert setup for NLS Pharmaceutics AG Equity Warrant performanceEarnings Growth Summary & Long-Term Safe Return Strategies - Newser
Developing predictive dashboards with NLS Pharmaceutics AG data2025 Growth vs Value & AI Based Buy/Sell Signal Reports - Newser
What MACD signals say about NLS Pharmaceutics AG Equity WarrantJuly 2025 Technicals & Verified Swing Trading Watchlists - Newser
Published on: 2025-09-08 20:53:31 - Newser
NLS Pharmaceutics AG stock prediction for this week2025 Top Gainers & Fast Entry Momentum Alerts - Newser
NLS Pharmaceutics AG stock retracement – recovery analysisPortfolio Value Summary & Safe Capital Growth Stock Tips - Newser
Is NLS Pharmaceutics AG stock bottoming out2025 Performance Recap & AI Forecast Swing Trade Picks - Newser
Is NLS Pharmaceutics AG Equity Warrant forming a reversal patternBuy Signal & Safe Capital Growth Plans - Newser
NLS Pharmaceutics AG Equity Warrant Recovery Potential Based on Technical ToolsWeekly Stock Report & Smart Investment Allocation Insights - beatles.ru
Will earnings trigger a reversal in NLS Pharmaceutics AG Equity WarrantJuly 2025 Rallies & AI Powered Buy and Sell Recommendations - Newser
Is this a good reentry point in NLS Pharmaceutics AG Equity Warrant2025 Institutional Moves & Reliable Breakout Forecasts - Newser
Published on: 2025-09-08 07:19:40 - Newser
Signal strength of NLS Pharmaceutics AG Equity Warrant stock in tech scanners2025 Institutional Moves & Weekly Top Performers Watchlists - Newser
Top chart patterns to watch in NLS Pharmaceutics AG Equity WarrantJuly 2025 Momentum & Risk Controlled Swing Trade Alerts - Newser
Volatility clustering patterns for NLS Pharmaceutics AG Equity Warrant2025 Market Outlook & Low Drawdown Momentum Trade Ideas - Newser
Can NLS Pharmaceutics AG stock double in the next yearJuly 2025 Levels & AI Forecast Swing Trade Picks - خودرو بانک
Earnings visualization tools for NLS Pharmaceutics AG2025 Top Gainers & Fast Entry Momentum Alerts - Newser
What’s the recovery path for long term holders of NLS Pharmaceutics AG Equity WarrantEarnings Miss & Long-Term Growth Stock Strategies - Newser
Using RSI to spot recovery in NLS Pharmaceutics AGWeekly Trend Report & Verified Short-Term Trading Plans - Newser
Using Bollinger Bands to evaluate NLS Pharmaceutics AGJuly 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - Newser
Key metrics from NLS Pharmaceutics AG Equity Warrant’s quarterly dataExit Point & Fast Exit and Entry Trade Guides - Newser
NLS Pharmaceutics and Kadimastem Secure Hong Kong Patent for Diabetes Therapy - TipRanks
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):